BioMarin Pharma (BMRN) Tops Q3 EPS by 38c; raises guidance

BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of $0.91, $0.38 better than the analyst estimate of $0.53. Revenue for the quarter came in at $746 million versus the consensus estimate of $703.14 million.

GUIDANCE:

BioMarin Pharma sees FY2024 EPS of $3.25-$3.35, versus the consensus of $3.22. BioMarin Pharma sees FY2024 revenue of $2.79-2.825 billion, versus the consensus of $2.799 billion.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• JPMorgan Reiterates Overweight Rating on Legrand SA (LR:FP) (LGRDY) and Places on Positive Catalyst Watch
• Goldman Sachs Downgrades Schindler Holding AG (SCHN:SW) (SHLAF) to Sell